Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Analyst Ratings
Strong Buy
3 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
FHTX Stock 12 Month Forecast
Average Price Target
$8.67
▲(82.53%Upside)
| Highest Price Target$13.00 | Average Price Target$8.67 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$5
Hold
5.26%
Upside
Reiterated
06/18/25
Foghorn Therapeutics' stock is significantly impacted by its financial distress, with persistent losses and negative equity as key concerns. Moderate technical indicators provide some bullish signals, but the poor valuation metrics, due to ongoing losses and lack of dividends, weigh heavily on the overall score.
Morgan Stanley
$4
Hold
-15.79%
Downside
Reiterated
06/12/25
H.C. Wainwright
$13
Buy
173.68%
Upside
Reiterated
05/15/25
Citizens JMP
$9
Buy
89.47%
Upside
Reiterated
05/15/25
TD Cowen
―
Buy
―
Reiterated
05/14/25
B.Riley Financial
$10
Buy
110.53%
Upside
Initiated
01/29/25
Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic DevelopmentsWe are initiating coverage of Foghorn Therapeutics Inc. (FHTX) with a Buy rating and a 12-month price target of $10/share. Our investment thesis centers on the company’s strategy to inactivate or degrade SMARCA2 in SMARCA-mutated cancers, representing a potentially significant market opportunity accounting for ~5% of all solid tumors. We view FHTX’s lead asset, FHD-909, a selective SMARCA2 inhibitor currently in a Phase I dose-escalating study, as the primary value driver. Despite FHD-909’s key differentiated attributes and robust preclinical data, we think the Street is undervaluing this program due to disappointing early efficacy data from Prelude’s SMARCA2 degrader (PRT3789), which missed sustaining high SMARCA2 degradation under the weekly dosing regimen.
Jefferies
$14
Buy
194.74%
Upside
Assigned
12/16/24
Wedbush
$13
Buy
173.68%
Upside
Reiterated
08/09/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$5
Hold
5.26%
Upside
Reiterated
06/18/25
Foghorn Therapeutics' stock is significantly impacted by its financial distress, with persistent losses and negative equity as key concerns. Moderate technical indicators provide some bullish signals, but the poor valuation metrics, due to ongoing losses and lack of dividends, weigh heavily on the overall score.
Morgan Stanley
$4
Hold
-15.79%
Downside
Reiterated
06/12/25
H.C. Wainwright
$13
Buy
173.68%
Upside
Reiterated
05/15/25
Citizens JMP
$9
Buy
89.47%
Upside
Reiterated
05/15/25
TD Cowen
―
Buy
―
Reiterated
05/14/25
B.Riley Financial
$10
Buy
110.53%
Upside
Initiated
01/29/25
Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic DevelopmentsWe are initiating coverage of Foghorn Therapeutics Inc. (FHTX) with a Buy rating and a 12-month price target of $10/share. Our investment thesis centers on the company’s strategy to inactivate or degrade SMARCA2 in SMARCA-mutated cancers, representing a potentially significant market opportunity accounting for ~5% of all solid tumors. We view FHTX’s lead asset, FHD-909, a selective SMARCA2 inhibitor currently in a Phase I dose-escalating study, as the primary value driver. Despite FHD-909’s key differentiated attributes and robust preclinical data, we think the Street is undervaluing this program due to disappointing early efficacy data from Prelude’s SMARCA2 degrader (PRT3789), which missed sustaining high SMARCA2 degradation under the weekly dosing regimen.
Jefferies
$14
Buy
194.74%
Upside
Assigned
12/16/24
Wedbush
$13
Buy
173.68%
Upside
Reiterated
08/09/24
Best Analysts Covering Foghorn Therapeutics
1 Month
xxx
Success Rate
6/10 ratings generated profit
Average Return
+18.72%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +18.72% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
+17.68%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +17.68% per trade.
1 Year
Success Rate
4/10 ratings generated profit
Average Return
-7.02%
reiterated a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -7.02% per trade.
2 Years
xxx
Success Rate
4/10 ratings generated profit
Average Return
-18.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -18.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
FHTX Analyst Recommendation Trends
Rating
Jan 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
5
5
5
6
5
Buy
2
2
2
2
1
Hold
2
3
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
10
8
9
7
Each month's total comprises the sum of three months' worth of ratings.
FHTX Financial Forecast
FHTX Stock Forecast FAQ
What is FHTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Foghorn Therapeutics’s 12-month average price target is 8.67.
What is FHTX’s upside potential, based on the analysts’ average price target?
Foghorn Therapeutics has 82.53% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FHTX a Buy, Sell or Hold?
Foghorn Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.
What is Foghorn Therapeutics’s price target?
The average price target for Foghorn Therapeutics is 8.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $13.00 ,the lowest forecast is $4.00. The average price target represents 82.53% Increase from the current price of $4.75.
The highest analyst price target is $13.00 ,the lowest forecast is $4.00. The average price target represents 82.53% Increase from the current price of $4.75.
What do analysts say about Foghorn Therapeutics?
Foghorn Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of FHTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.